Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Aukelso"

4 News Found

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market
Biopharma | April 08, 2026

Biocon launches denosumab biosimilars Bosaya and Aukelso in US market

Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market

Biocon Biologics secures US market entry date for Bosaya and Aukelso, Denosumab biosimilars
News | October 01, 2025

Biocon Biologics secures US market entry date for Bosaya and Aukelso, Denosumab biosimilars

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars
Drug Approval | September 17, 2025

Biocon Biologics receives FDA approval for Bosaya and Aukelso biosimilars

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World
News | December 03, 2025

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

Latest Stories

JP Nadda highlights preventive healthcare push on World Health Day

Asia emerges new hotspot for healthcare ransomware, says report

Solara Active Pharma dispatches final rights share call notice; Rs 112.5 per share due by May 7

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging